<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056715</url>
  </required_header>
  <id_info>
    <org_study_id>iRT-001-2019</org_study_id>
    <nct_id>NCT04056715</nct_id>
  </id_info>
  <brief_title>Extended ECG Monitoring in HCM Patients</brief_title>
  <acronym>EXAMINE-HCM</acronym>
  <official_title>Extended Ambulatory Monitoring With iRhythm Zio XT Improves Care of Patients With Hypertrophic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iRhythm Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iRhythm Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine, among a large cohort of 300 consecutive patients
      with hypertrophic cardiomyopathy, if extended ambulatory monitoring using the iRhythm
      Technologies, Inc. Zio XT device results in identifying a greater burden of nonsustained
      ventricular tachyarrhythmia (nsVT) compared to current ACCF/AHA guideline recommended 48-hour
      monitoring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optimal duration to monitor patients for identifying nsVT remains unclear. The investigators
      aim to determine the prevalence and burden of nsVT with longer term monitoring with the
      iRhythm Zio XT device over a 2-week period vs. 48 hours; and whether, this greater burden of
      nsVT compared to conventional shorter monitoring potentially identifies a subset of HCM
      patients who may be at higher risk of sudden cardiac death.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of nsVT runs through 14 days of ambulatory cardiac monitoring, as compared to the first 48 hours.</measure>
    <time_frame>14 days</time_frame>
    <description>Compare the number of nsVT runs detected between the first 48 hours vs 2 weeks of ambulatory cardiac monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of atrial fibrillation runs through 14 days of ambulatory cardiac monitoring, as compared to the first 48 hours.</measure>
    <time_frame>14 days</time_frame>
    <description>Compare the number of AF runs detected between the first 48 hours vs 2 weeks of ambulatory cardiac monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinical management decisions based on 14 days of ambulatory cardiac monitoring, as compared to the first 48 hours ambulatory cardiac monitoring.</measure>
    <time_frame>14 days</time_frame>
    <description>Compare the number clinical decisions based on the first 48 hours vs 14 days of ambulatory cardiac monitoring.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Nonsustained Ventricular Tachycardia</condition>
  <condition>Ventricular Tachycardia</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>HCM Group</arm_group_label>
    <description>Eligible HCM subjects will be monitored for arrhythmias with a 2-week ECG patch.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zio XT</intervention_name>
    <description>ambulatory cardiac monitoring device</description>
    <arm_group_label>HCM Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from the hypertrophic cardiomyopathy population will be recruited.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 18 to 65 years of age at time of informed consent and must not be a
             member of a vulnerable population.

          -  Subject has been diagnosed with hypertrophic cardiomyopathy, as defined by a maximal
             LV wall thickness of â‰¥15 mm anywhere in LV wall, in absence of another cause that
             could be responsible for the LV hypertrophy.

          -  Subject eligible to receive the Zio XT device per the current approved indications for
             use.

        Exclusion Criteria:

          -  Subject with pacemaker

          -  Known skin allergies or reaction to adhesives

          -  The investigator deems a condition that could limit a subject's ability or
             unwillingness to participate in the study, comply with study required monitoring
             and/or follow-up visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Maron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Higgins</last_name>
    <phone>617-636-4928</phone>
    <email>dhiggins@tuftsmedicalcenter.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gaurav Das</last_name>
    <phone>617-636-4928</phone>
    <email>gdas@tuftsmedicalcenter.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Maron, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>electrocardiography</keyword>
  <keyword>electrocardiogram</keyword>
  <keyword>mobile cardiac monitoring</keyword>
  <keyword>ambulatory monitoring</keyword>
  <keyword>ECG</keyword>
  <keyword>EKG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

